The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

A new vaccine provides hope for treating and even preventing the highly contagious and difficult-to-treat Clostridioides ...

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent ...

In an era where viral outbreaks can escalate into global pandemics with alarming speed, the ability to quickly develop new ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

The trial will evaluate the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403 ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...